MedTrace Logo

Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients

NCT06152562 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2023-11-30

No results posted yet for this study

Summary

The aim of this study is to evaluate the incidence of any hemocompatibility related adverse event (HRAE) after LVAD placement in patients responsive to a standard aspirin dose using point-of-care platelet inhibition monitoring compared with initial non-responders who were then up-titrated to achieve a therapeutic response using individualized acetylsalicylic acid (ASA) therapy. Second, to investigate whether patients exhibit temporal changes in ASA sensitivity during LVAD support.

Conditions

  • End-stage Heart Failure
  • Cardiomyopathies
  • Mechanical Circulatory Support

Interventions

DIAGNOSTIC_TEST

VerifyNow antiplatelet therapy response test

VerifyNow testing after minimum of 2 hours and at latest 24 hours after the first four dosis of ASA

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2023-11-28
Completion
2023-11-28

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06152562 on ClinicalTrials.gov